Research progress on the evaluation of cancer-related sarcopenia and its impact on anti-cancer therapy
10.16151/j.1007-810x.2025.03.010
- VernacularTitle:肿瘤相关性肌肉减少症的评估及对抗肿瘤治疗影响的研究进展
- Author:
Yi-Yin ZHAN
1
;
Hua JIANG
;
Xing-Yue ZHAI
Author Information
1. 大连医科大学附属第二医院临床营养科,辽宁 大连 116023
- Keywords:
Cancer-related sarcopenia;
Evaluation;
Impact on anti-cancer therapy;
Intervention for sarcopenia
- From:
Parenteral & Enteral Nutrition
2025;32(3):184-188,192
- CountryChina
- Language:Chinese
-
Abstract:
One of the most common adverse reactions associated with cancer and its treatment is sarcopenia,a syndrome primarily caused by the disruption of muscle homeostasis,leading to excessive muscle atrophy and decreased muscle strength.For cancer patients,sarcopenia reflects not only a state of muscle mass loss but also serves as an important factor affecting treatment efficacy and survival rates.However,cancer-related sarcopenia often has a more insidious onset,is not visible to the naked eye,and is easily overlooked.Therefore,it is necessary to recognize the dangers of sarcopenia throughout the cancer treatment process and to identify low muscle mass early.In recent years,as healthcare professionals have increasingly focused on sarcopenia,research on cancer-related sarcopenia has gradually deepened,with new advancements in its assessment,diagnosis,intervention,and impact on anti-cancer treatment.This article provides a review of these key areas to offer a theoretical basis for the clinical practice of cancer-related sarcopenia.
